Compare GRFS & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | MMED |
|---|---|---|
| Founded | 1940 | 1983 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.7B |
| IPO Year | 2008 | 2025 |
| Metric | GRFS | MMED |
|---|---|---|
| Price | $8.21 | $16.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 16 |
| Target Price | $10.37 | ★ $25.33 |
| AVG Volume (30 Days) | 699.5K | ★ 6.3M |
| Earning Date | 07-28-2022 | 11-24-2026 |
| Dividend Yield | ★ 3.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $3,102,000,000.00 |
| Revenue This Year | $2.18 | $10.76 |
| Revenue Next Year | $6.15 | $8.51 |
| P/E Ratio | $18.67 | ★ N/A |
| Revenue Growth | N/A | ★ 14.25 |
| 52 Week Low | $6.96 | $10.65 |
| 52 Week High | $9.77 | $24.43 |
| Indicator | GRFS | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 38.13 |
| Support Level | $7.52 | $14.70 |
| Resistance Level | $8.29 | $17.86 |
| Average True Range (ATR) | 0.24 | 0.98 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 0.54 | 3.03 |
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
While MiniMed recently became an independent company again, it began in the 1980s as an upstart pioneer in developing and commercializing insulin pump therapy. Medtronic acquired MiniMed in 2001 and then spun it out in 2026 (though Medtronic still owns roughly 90% of MiniMed shares, which will be relayed to its shareholders as a tax-free distribution in the foreseeable future). MiniMed is the leader in traditional, tubed insulin pumps and also offers continuous glucose monitors, smart insulin pens, and other consumables.